DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that it is the recipient of Frost & Sullivan’s 2007 North American Technology Innovation Award for the field of Anti-Infective Coatings. Each year, this award is presented to a company that has demonstrated excellence in new products and technologies within its industry. Cerashield™ uses Ceragenix’s proprietary compound that mimics the activity of a key component of the human body’s innate immune system to help prevent bacterial colonization and biofilm growth on medical devices such as catheters and endotracheal tubes. Bacterial colonization and biofilm growth on medical devices can lead to serious infections which increase the patient’s length of stay, results in billions of dollars in additional health care costs and are the direct cause of preventable pain, suffering and death.
